Comparison of outcome and toxicity of postoperative intensity‐modulated radiation therapy with two‐dimensional radiotherapy in patients with soft tissue sarcoma of extremities and... by Jianyang Wang, Yongwen Song, Xinfan Liu, Jing Jin, Weihu Wang, Zihao Yu, Yueping Liu, Ning Li, Hui Fang, Hua Ren, Yuan Tang, Yu Tang, Bo Chen, Ningning Lu, Shunan Qi, Shulian Wang, Yexiong Li

“…Compared to 2D‐RT group, the IMRT group had higher 5‐year local recurrence‐free survival (LRFS) (91.1% vs 80.8%; P = 0.029), distant metastasis‐free survival (DMFS) (80.0% vs 69.7%; P = 0.048), disease‐free survival (DFS) (75.2% vs 59.2%; P = 0.021), and overall survival (OS) (90.2% vs 81.0%; P = 0.029). …”
Get full text

Reduced p63 expression is linked to unfavourable prognosis in muscle‐invasive urothelial carcinoma of the bladder by Kira Furlano, Henning Plage, Sebastian Hofbauer, Sarah Weinberger, Bernhard Ralla, Annika Fendler, Florian Roßner, Simon Schallenberg, Sefer Elezkurtaj, Martina Kluth, Maximilian Lennartz, Niclas C. Blessin, Andreas H. Marx, Henrik Samtleben, Margit Fisch, Michael Rink, Marcin Slojewski, Krystian Kaczmarek, Thorsten Ecke, Stefan Koch, Nico Adamini, Sarah Minner, Ronald Simon, Guido Sauter, Joachim Weischenfeldt, Tobias Klatte, Thorsten Schlomm, David Horst, Henrik Zecha

“…Within 1018 pT2‐4 carcinomas treated by cystectomy, low p63 expression was linked to nodal metastasis (p = 0.0028) and overall survival (p = 0.0005). …”
Get full text

Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR by Pui Yeng Lam, Natacha Omer, Josh K. M. Wong, Cui Tu, Louisa Alim, Gustavo R. Rossi, Maria Victorova, Hannah Tompkins, Cheng‐Yu Lin, Ahmed M. Mehdi, Amos Choo, Melissa R. Elliott, Elaina Coleborn, Jane Sun, Timothy Mercer, Orazio Vittorio, Lachlan J. Dobson, Alexander D. McLellan, Andrew Brooks, Zewen Kelvin Tuong, Seth W. Cheetham, Wayne Nicholls, Fernando Souza‐Fonseca‐Guimaraes

“…These cancers share common challenges, including high rates of metastasis, recurrence or treatment resistance, leading to a 5‐year survival rate of approximately 20% for patients with advanced disease stages. …”
Get full text

Clinical and genetic drivers of oligo-metastatic disease in colon cancer by Alessandro Ottaiano, Mariachiara Santorsola, Roberto Sirica, Annabella Di Mauro, Antonella Di Carlo, Monica Ianniello, Francesco Sabbatino, Rosa Castiello, Francesca Del Peschio, Marco Cascella, Francesco Perri, Maurizio Capuozzo, Nicola Martucci, Edoardo Mercadante, Valentina Borzillo, Rossella Di Franco, Francesco Izzo, Vincenza Granata, Carmine Picone, Antonella Petrillo, Massimiliano Berretta, Salvatore Stilo, Luca Tarotto, Anna Chiara Carratù, Gerardo Ferrara, Madhura Tathode, Alessia Maria Cossu, Marco Bocchetti, Michele Caraglia, Guglielmo Nasti, Giovanni Savarese

“…Overall survival (OS) was determined from metastasis diagnosis until death using Kaplan–Meier analysis. …”
Get full text

GsMTx-4 venom toxin antagonizes biophysical modulation of metastatic traits in human osteosarcoma cells by Arianna Buglione, Giulia Alloisio, Chiara Ciaccio, David Becerril Rodriguez, Simone Dogali, Marco Luce, Stefano Marini, Antonio Cricenti, Magda Gioia

“…Thus, suggesting its potential as a promising therapeutic agent for targeting osteosarcoma metastasis…”
Get full text